Curium Reportedly Eyes $7B Buyout of Lantheus Holdings

What's Happening French radiopharmaceutical giant Curium is in talks to acquire Lantheus Holdings for roughly $7 billion, according to a Bloomberg report. If the deal goes through, it would be one of the biggest moves yet in the fast-growing nuclear medicine space — and it would take a major U.S. diagnostics player off the public market.

Lantheus is best known for PYLARIFY, a PET imaging agent used to detect prostate cancer, along with a broader portfolio of diagnostic and therapeutic radiopharmaceuticals. The company has built a strong niche as imaging technology becomes central to how doctors diagnose and monitor cancer treatment. Curium, meanwhile, is a privately held European company (backed by private equity firm CapVest) that's been aggressively expanding its footprint in nuclear medicine, making Lantheus a logical — if pricey — target.

Why This Deal Makes Sense Radiopharmaceuticals are one of the hottest corners of healthcare right now. These are drugs and diagnostic tools that use radioactive isotopes to find and, increasingly, treat cancer at the cellular level. Big Pharma has been circling the space for years — Novartis, AstraZeneca, Eli Lilly and others have all made acquisitions here — because the technology promises more precise, less invasive cancer care.

Lantheus has positioned itself as a leader in this niche, and its stock has been a strong performer as PYLARIFY sales grew. A $7 billion price tag would represent a significant premium and validation of that growth story, and it would hand Curium instant scale and a foothold in the massive U.S. market.

What's Still Unclear As of now, this is being reported as talks — not a signed deal. Details on price per share, financing, or timeline haven't been confirmed publicly. Deals like this can also fall apart or get revised before anything is finalized, so treat the $7 billion figure as a working number rather than gospel.

What to Watch Next If you're tracking this as an investor or just a healthcare-industry watcher, keep an eye on: official confirmation from either company, any competing bids (deals this size sometimes attract rival suitors), and regulatory reaction, since radiopharmaceutical consolidation could draw antitrust scrutiny given how concentrated the imaging-agent supply chain already is.